Alexa6000 Anti-Xa IU/0.6 ml

Enoxaparin sodium is used to prevent and treat blood clots (thromboembolism) in a range of clinical settings.

• Prevention of deep vein thrombosis (DVT) after abdominal surgery, hip replacement surgery, or knee replacement surgery
• Prevention of DVT in medical patients with severely restricted mobility during acute illness
• Treatment of acute DVT, with or without pulmonary embolism, given together with an oral anticoagulant such as warfarin
• Reducing the risk of ischemic complications in unstable angina and non-ST-elevation myocardial infarction (NSTEMI), used together with aspirin
• Treatment of acute ST-elevation myocardial infarction (STEMI), used together with aspirin

Each mL of injection contains Alexa 6000 Anti-Xa IU/0.6 ml 100 mg. It is supplied as single-dose prefilled syringes (commonly 20 mg, 40 mg, 60 mg, 80 mg and 100 mg strengths) and as a multiple-dose vial. Exact strengths, syringe sizes and presentations may vary by product; refer to the specific product's packaging.

Enoxaparin sodium is a low molecular weight heparin (LMWH), an injectable anticoagulant used to prevent and treat harmful blood clots. It is given by subcutaneous injection (and in some indications by an initial intravenous dose) and works by reducing the blood's ability to clot excessively. Enoxaparin is widely used after major surgery, during acute illness with restricted mobility, and in the management of acute coronary syndromes and venous thromboembolism.

Therapeutic Class: Anticoagulant (Antithrombotic agent)

Enoxaparin is obtained by controlled depolymerization of unfractionated heparin. It has a mean molecular weight of approximately 4,500 daltons and predominantly inhibits Factor Xa, with weaker activity against thrombin (Factor IIa), compared to unfractionated heparin.

Subcutaneous bioavailability is approximately 90%. The elimination half-life is about 3 to 4.5 hours after a single dose and increases to roughly 7 hours with repeated dosing. Enoxaparin is eliminated mainly through the kidneys, so drug exposure increases in patients with renal impairment.

Alexa 6000 Anti-Xa IU/0.6 ml is given by subcutaneous injection into the anterolateral or posterolateral abdominal wall, alternating sides with each dose. The intravenous bolus route is used only for the specific STEMI regimen described above, using the intravenous formulation as directed. Alexa 6000 Anti-Xa IU/0.6 ml should not be given by intramuscular injection.

• Do not expel the air bubble from a prefilled syringe before injecting, unless the dose needs adjusting
• Insert the entire length of the needle into a skin fold held between thumb and forefinger
• Do not rub the injection site after administration
• Rotate injection sites to reduce bruising

Concomitant use of Enoxaparin sodium with other agents that affect bleeding risk should be assessed by a healthcare professional. These include:

• Other anticoagulants (e.g., warfarin, direct oral anticoagulants)
• Antiplatelet agents such as aspirin, clopidogrel, and other NSAIDs
• Systemic corticosteroids and dextran

Combined use may increase the risk of bleeding and requires careful clinical monitoring; patients should not stop or start any other medicine without consulting their doctor.

Common side effects of Alexa 6000 Anti-Xa IU/0.6 ml

• Bruising, pain, or a small lump at the injection site
• Minor bleeding (e.g., nosebleeds, bleeding gums)
• Mild, transient reduction in platelet count
• Elevated liver enzymes

Serious side effects (seek urgent medical attention)

• Signs of major bleeding: unusual bruising, blood in urine or stool, prolonged bleeding from cuts, severe headache or weakness
• Heparin-induced thrombocytopenia: a sharp drop in platelets, sometimes with new clotting
• Signs of spinal or epidural bleeding after neuraxial anesthesia: back pain, numbness, or weakness in the legs, or bowel/bladder dysfunction
• Signs of an allergic reaction: rash, swelling, difficulty breathing

Pregnancy

Pregnancy increases the risk of blood clots, and Alexa 6000 Anti-Xa IU/0.6 ml does not cross the placenta. It is commonly used for VTE prevention and treatment during pregnancy when clinically indicated. Pregnant women with mechanical prosthetic heart valves may be at higher risk of thromboembolic complications, including when anticoagulated with Alexa 6000 Anti-Xa IU/0.6 ml, and require specialist obstetric and cardiology input.

Breastfeeding

It is not well established whether Alexa 6000 Anti-Xa IU/0.6 ml passes into human breast milk in clinically significant amounts. Available limited data suggest minimal transfer. Use during breastfeeding should be guided by a healthcare professional weighing the mother's need for anticoagulation against any potential infant exposure.

• Spinal/epidural hematoma: Patients receiving neuraxial anesthesia or spinal puncture while on enoxaparin are at risk of spinal or epidural hematoma, which can cause long-term or permanent paralysis. Timing between enoxaparin doses and neuraxial procedures needs careful clinical planning.
• Thrombocytopenia and HIT: Platelet counts should be monitored, particularly in the first weeks of therapy.
• Renal impairment: Increased drug exposure and bleeding risk; dose adjustment needed in severe impairment.
• Hepatic impairment: Use with caution; increased bleeding risk has been reported.
• Low body weight: Patients under 45 kg may have increased exposure and bleeding risk and should be monitored closely.
• Mechanical heart valves: Use for thromboprophylaxis in patients with mechanical prosthetic heart valves has been associated with valve thrombosis in some cases; specialist guidance is recommended.
• Bleeding risk is increased with concurrent use of other drugs affecting hemostasis, recent surgery, or invasive procedures.

Accidental overdose of Alexa 6000 Anti-Xa IU/0.6 ml can cause bleeding complications, which may be serious depending on the dose and site of bleeding. Signs may include unusual bruising, blood in urine or stool, or symptoms of internal bleeding such as severe abdominal or back pain, dizziness, or weakness. Suspected overdose or serious bleeding requires immediate emergency medical care; protamine sulfate can partially reverse Alexa 6000 Anti-Xa IU/0.6 ml 's anticoagulant effect under medical supervision, but reversal is incomplete.

Store as directed on the specific product's packaging, generally at controlled room temperature and protected from light. Do not freeze. Storage conditions and any in-use stability period may vary by manufacturer and presentation (prefilled syringe versus multi-dose vial); follow the instructions provided with the specific product.

• Elderly: May have reduced renal function; monitor closely for bleeding, especially at doses used for STEMI, where dosing is adjusted for patients 75 years and older.
• Renal impairment: Dose reduction required in severe impairment (creatinine clearance under 30 mL/min); close monitoring recommended.
• Hepatic impairment: Limited data; use with caution and monitor for bleeding.
• Low body weight: Increased risk of bleeding; monitor closely.

Duration varies by indication: surgical DVT prophylaxis is typically continued for the duration of the risk period (commonly 6 to 14 days, sometimes longer after major orthopedic surgery, per the prescriber's protocol); treatment of acute DVT/PE is generally continued for at least 5 days and until a therapeutic oral anticoagulant effect is achieved; acute coronary syndrome regimens are typically continued during the acute hospital treatment course. The treating physician determines the exact duration based on clinical response and ongoing risk.

Drug Class: Low molecular weight heparin (LMWH)

Enoxaparin works by boosting the activity of antithrombin, a natural protein that inhibits clotting factors in the blood. This enhanced antithrombin activity mainly blocks Factor Xa, an enzyme central to the clotting cascade, which reduces the formation of new clots without requiring the close laboratory monitoring needed with unfractionated heparin.

Enoxaparin is not routinely established for general pediatric use through standard prescribing information, though it is used in some pediatric anticoagulation settings under specialist supervision. Pediatric dosing differs substantially from adult dosing and should only be determined by a pediatric hematology or specialist protocol, with close monitoring, rather than adult-dose extrapolation.